S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:BPTS

Biophytis Stock Forecast, Price & News

$6.93
+0.00 (+0.00 %)
(As of 10/18/2021 04:00 PM ET)
Add
Compare
Today's Range
$6.90
$6.93
50-Day Range
$6.93
$9.42
52-Week Range
$6.40
$18.50
Volume7,700 shs
Average Volume8,641 shs
Market Capitalization$83.69 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.


Biophytis logo

About Biophytis

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.

Headlines

Biophytis SA (NASDAQ:BPTS) Short Interest Update
October 13, 2021 |  americanbankingnews.com
Biophytis (NASDAQ:BPTS) Shares Down 1%
October 13, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTS
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$83.69 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1337th out of 1,361 stocks

Pharmaceutical Preparations Industry

658th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Biophytis (NASDAQ:BPTS) Frequently Asked Questions

What stocks does MarketBeat like better than Biophytis?

Wall Street analysts have given Biophytis a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biophytis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biophytis?

Biophytis saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 2,000 shares, a drop of 72.2% from the September 15th total of 7,200 shares. Based on an average trading volume of 1,500 shares, the days-to-cover ratio is presently 1.3 days.
View Biophytis' Short Interest
.

Who are Biophytis' key executives?

Biophytis' management team includes the following people:
  • Mr. Stanislas Veillet, Chairman & CEO (Age 55, Pay $443.28k)
  • Ms. Evelyne Nguyen, Chief Financial Officer (Age 59)
  • Mr. Waly Dioh, Chief Operating Officer (Age 52)
  • Dr. Pierre J. Dilda, Chief Scientific Officer (Age 51)
  • Dr. Rene Lafont, Scientific Advisor & Member of Scientific Advisory Board (Age 75)
  • Dr. Samuel Agus, Chief Medical Officer (Age 53)
  • Ms. _ Teylan, Financial Controller

When did Biophytis IPO?

(BPTS) raised $20 million in an IPO on Wednesday, February 10th 2021. The company issued 1,200,000 shares at a price of $15.00-$18.00 per share. H.C. Wainwright served as the underwriter for the IPO.

What is Biophytis' stock symbol?

Biophytis trades on the NASDAQ under the ticker symbol "BPTS."

How do I buy shares of Biophytis?

Shares of BPTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biophytis' stock price today?

One share of BPTS stock can currently be purchased for approximately $6.93.

How much money does Biophytis make?

Biophytis has a market capitalization of $83.69 million.

How many employees does Biophytis have?

Biophytis employs 2,020 workers across the globe.

What is Biophytis' official website?

The official website for Biophytis is www.biophytis.com.

Where are Biophytis' headquarters?

How can I contact Biophytis?

Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The company can be reached via phone at 33-1-44-37-23-00.


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.